2399 related articles for article (PubMed ID: 11786451)
21. Antiplatelet agents and anticoagulants for hypertension.
Lip GY; Felmeden DC; Dwivedi G
Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD003186. PubMed ID: 22161375
[TBL] [Abstract][Full Text] [Related]
22. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Montalescot G
Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
[TBL] [Abstract][Full Text] [Related]
23. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.
Squizzato A; Keller T; Romualdi E; Middeldorp S
Cochrane Database Syst Rev; 2011 Jan; (1):CD005158. PubMed ID: 21249668
[TBL] [Abstract][Full Text] [Related]
24. Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Meade T
Handb Exp Pharmacol; 2012; (210):565-605. PubMed ID: 22918747
[TBL] [Abstract][Full Text] [Related]
25. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet Therapy After Noncardioembolic Stroke.
Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
[TBL] [Abstract][Full Text] [Related]
27. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
Antiplatelet Trialists' Collaboration
Br Med J (Clin Res Ed); 1988 Jan; 296(6618):320-31. PubMed ID: 3125883
[TBL] [Abstract][Full Text] [Related]
28. Antiplatelet agents and anticoagulants for hypertension.
Lip GY; Felmeden DC
Cochrane Database Syst Rev; 2004; (3):CD003186. PubMed ID: 15266473
[TBL] [Abstract][Full Text] [Related]
29. Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.
Lewis SR; Pritchard MW; Schofield-Robinson OJ; Alderson P; Smith AF
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012584. PubMed ID: 30019463
[TBL] [Abstract][Full Text] [Related]
30. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Tran H; Anand SS
JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
[TBL] [Abstract][Full Text] [Related]
31. Antiplatelet therapy in the prevention of ischaemic stroke.
Verry M; Panak E; Cazenave JP
Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242
[TBL] [Abstract][Full Text] [Related]
32. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Kamal AK; Naqvi I; Husain MR; Khealani BA
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD008076. PubMed ID: 21249700
[TBL] [Abstract][Full Text] [Related]
33. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
[TBL] [Abstract][Full Text] [Related]
34. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
; Baigent C; Blackwell L; Collins R; Emberson J; Godwin J; Peto R; Buring J; Hennekens C; Kearney P; Meade T; Patrono C; Roncaglioni MC; Zanchetti A
Lancet; 2009 May; 373(9678):1849-60. PubMed ID: 19482214
[TBL] [Abstract][Full Text] [Related]
35. Evidence with antiplatelet therapy and ADP-receptor antagonists.
Easton JD
Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
[TBL] [Abstract][Full Text] [Related]
36. Antiplatelet agents and anticoagulants for hypertension.
Shantsila E; Kozieł-Siołkowska M; Lip GY
Cochrane Database Syst Rev; 2022 Jul; 7():CD003186. PubMed ID: 35900898
[TBL] [Abstract][Full Text] [Related]
37. Triflusal for preventing serious vascular events in people at high risk.
Costa J; Ferro JM; Matias-Guiu J; Alvarez-Sabin J; Torres F
Cochrane Database Syst Rev; 2005 Jul; (3):CD004296. PubMed ID: 16034926
[TBL] [Abstract][Full Text] [Related]
38. Antiplatelet therapy and anticoagulation in patients with hypertension.
Griffin G
Am Fam Physician; 2005 Mar; 71(5):897-9. PubMed ID: 15768617
[TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
[TBL] [Abstract][Full Text] [Related]
40. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Mehta SR; Yusuf S
J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):79S-88S. PubMed ID: 12644345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
